Man Group
PCRX icon

Man Group’s Pacira BioSciences PCRX Stock Holding History

Man Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
+125,370
New +$2.96M 0.01% 1352
2025
Q3 		– Sell
-26,302
Closed -$629K – 2404
2025
Q2 		$629K Sell
26,302
-22,333
-46% -$563K ﹤0.01% 1760
2025
Q1 		$1.21M Buy
+48,635
New +$1.16M ﹤0.01% 1532
2024
Q4 		– Sell
-69,031
Closed -$1.04M – 2143
2024
Q3 		$1.04M Sell
69,031
-21,575
-24% -$369K ﹤0.01% 1489
2024
Q2 		$2.59M Buy
90,606
+37,821
+72% +$1.08M 0.01% 1265
2024
Q1 		$1.54M Sell
52,785
-26,098
-33% -$802K ﹤0.01% 1397
2023
Q4 		$2.66M Buy
+78,883
New +$2.31M 0.01% 1184
2023
Q3 		– Sell
-58,964
Closed -$2.13M – 1124
2023
Q2 		$2.36M Buy
+58,964
New +$2.44M 0.01% 1136
2023
Q1 		– Sell
-96,707
Closed -$3.85M – 1223
2022
Q4 		$3.73M Buy
+96,707
New +$4.71M 0.01% 936
2022
Q2 		– Hold
0
– – – 1396
2022
Q1 		– Sell
-5,244
Closed -$316K – 2308
2021
Q4 		$316K Buy
+5,244
New +$289K ﹤0.01% 1658
2021
Q1 		– Sell
-75,647
Closed -$4.53M – 1962
2020
Q4 		$4.53M Sell
75,647
-122,990
-62% -$7.2M 0.02% 859
2020
Q3 		$11.9M Sell
198,637
-11,642
-6% -$676K 0.05% 412
2020
Q2 		$11M Sell
210,279
-29,604
-12% -$1.24M 0.06% 332
2020
Q1 		$8.04M Buy
239,883
+156,663
+188% +$6.51M 0.05% 354
2019
Q4 		$3.77M Buy
83,220
+53,774
+183% +$2.28M 0.01% 1099
2019
Q3 		$1.12M Buy
29,446
+11,446
+64% +$457K ﹤0.01% 1397
2019
Q2 		$783K Buy
+18,000
New +$764K ﹤0.01% 1583
2019
Q1 		– Sell
-14,217
Closed -$612K – 2041
2018
Q4 		$612K Sell
14,217
-31,600
-69% -$1.47M ﹤0.01% 1586
2018
Q3 		$2.25M Buy
45,817
+33,018
+258% +$1.43M 0.01% 1371
2018
Q2 		$410K Buy
+12,799
New +$442K ﹤0.01% 1853

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's PCRX Position: Q2 2026 in Review

Man Group opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 125,370 shares worth $3.18M. The stake represents 0.01% of the portfolio and ranks #1352 among its holdings. This is a return to the name: Man Group previously reported a position in PCRX as recently as Q2 2025.

Man Group first reported a position in PCRX in Q2 2018 and has held it in 20 quarters since. The position peaked at $11.9M in Q3 2020. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Man Group held 125,370 shares of Pacira BioSciences worth $3.18M as of Q2 2026.
  • Pacira BioSciences was a new Man Group position in Q2 2026.
  • Pacira BioSciences made up 0.01% of Man Group's portfolio in Q2 2026, its #1352 holding.
  • Man Group first reported a position in Pacira BioSciences in Q2 2018 and has held it in 20 quarters since.
  • Man Group's Pacira BioSciences position peaked at $11.9M in Q3 2020.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.